83.9 F
San Fernando
Friday, Mar 29, 2024

Amgen’s Competing Drug Has Similar Results, Study Finds

Drug maker Roche Holding AG said over the weekend that a clinical trial for its anemia drug Cera showed it worked as well as Thousand Oaks biopharmaceutical giant Amgen’s Aranesp. Both drugs are used in patients with chronic kidney disease. Roche said the Phase III study of 324 patients found both Cera and Arnesp effective in 97 percent of subjects. The safety levels were both identical, the company said. Roche has been developing Cera for the past several years. Amgen has sued the company alleging it violated half-dozen patents on Epogen, which Amgen started selling in 2001. The case is slated to go to trial next fall.

Featured Articles

Related Articles